

**RECORDATI: 2015 CORPORATE EVENTS' CALENDAR**

Milan, 28<sup>th</sup> November 2014 – Pursuant to Article 2.6.2, paragraph 1, let. (b) of Borsa Italiana S.p.A.'s Regulation, Recordati S.p.A. hereby communicates the calendar of corporate events for 2015.

- 12<sup>th</sup> February** Board of Directors' meeting to approve the 2014 preliminary consolidated results.
- 5<sup>th</sup> March** Board of Directors' meeting to approve the 2014 consolidated financial statements and the draft of Recordati S.p.A.'s 2014 Financial Statements.
- 15<sup>th</sup> April** Shareholders' General Meeting to approve the 2014 Financial Statements.
- 5<sup>th</sup> May** Board of Directors' meeting to approve the 2015 first quarter interim management statement.
- 29<sup>th</sup> July** Board of Directors' meeting to approve the 2015 half-yearly report.
- 28<sup>th</sup> October** Board of Directors' meeting to approve the 2015 first nine months' interim management statement.

Recordati S.p.A. announces that the payment of the balance of the 2014 financial year dividend is planned for April 2015, while payment of the interim dividend for the 2015 financial year is planned for November 2015.

Recordati S.p.A. specifies that this press release is not a prevision of the existence of the conditions for the dividend distribution as per the above.

Any amendments to the above calendar will be promptly notified to the market.

*Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of around 4,000, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, in other Central and Eastern European countries, in Turkey, in North Africa and in the United States of America. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties within the urogenital therapeutic area and of treatments for rare diseases. Consolidated revenue for 2013 was € 941.6 million, operating income was € 195.4 million and net income was € 133.7 million.*

For further information:

Recordati website: [www.recordati.com](http://www.recordati.com)

**Investor Relations**

Marianne Tatschke  
(39)0248787393  
e-mail: [inver@recordati.it](mailto:inver@recordati.it)

**Media Relations**

Studio Noris Morano  
(39)0276004736, (39)0276004745  
e-mail: [norismorano@studionorismorano.com](mailto:norismorano@studionorismorano.com)

**RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.**

Sede Legale  
VIA M. CIVITALI, 1  
20148 MILANO, ITALIA  
TEL. (39) 0248787.1  
FAX (39) 0240073747

CAPITALE SOCIALE € 26.140.644,50 I.V.  
REG. IMP. MILANO N. 00748210150  
CODICE FISCALE/P.IVA 007482210150  
R.E.A. MILANO N. 401832

*Statements contained in this release, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intended to indicate the advisability of administering any product in any particular instance.*